TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Biofrontera ( (BFRI) ) has provided an update.
Biofrontera Inc. has announced that it has regained compliance with Nasdaq’s continued listing requirements under Listing Rules 5550(b)(1) and 5550(a)(2) as of November 4 and November 6, 2025, respectively. This compliance follows previous notifications of non-compliance due to the company’s stockholders’ equity and stock price falling below required thresholds earlier in 2025, impacting its market positioning and potentially averting delisting threats.
The most recent analyst rating on (BFRI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s overall score is driven by strong technical momentum and positive earnings call sentiment, offset by weak financial performance and valuation concerns. The company’s strategic shifts and growth prospects are promising, but profitability and cash flow challenges remain significant risks.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Average Trading Volume: 202,845
Technical Sentiment Signal: Buy
Current Market Cap: $11.52M
See more insights into BFRI stock on TipRanks’ Stock Analysis page.